April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
AAV-mediated antisense oligonucleotide-based therapy for CEP290-associated LCA
Author Affiliations & Notes
  • Alejandro Garanto
    Human Genetics, Radboud university medical centre, Nijmegen, Netherlands
  • Lonneke Duijkers
    Human Genetics, Radboud university medical centre, Nijmegen, Netherlands
  • Ru Xiao
    Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA
  • Luk H Vandenberghe
    Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA
  • Rob W J Collin
    Human Genetics, Radboud university medical centre, Nijmegen, Netherlands
  • Footnotes
    Commercial Relationships Alejandro Garanto, None; Lonneke Duijkers, None; Ru Xiao, None; Luk Vandenberghe, GenSight Biologics (C), GenSight Biologics (I), GlaxoSmithKline Beecham, ReGenX Biosciences (P), Novartis Pharmaceuticals (C); Rob Collin, Radboud university medical centre (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3312. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alejandro Garanto, Lonneke Duijkers, Ru Xiao, Luk H Vandenberghe, Rob W J Collin; AAV-mediated antisense oligonucleotide-based therapy for CEP290-associated LCA. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3312.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Leber congenital amaurosis (LCA) is a severe form of retinal degeneration that can be caused by mutations in more than 20 different genes. The most recurrent causative mutation is an intronic change in CEP290 (c.2991+1655A>G), that results in the insertion of a cryptic exon into CEP290 mRNA. Antisense oligonucleotides (AONs) are small RNA molecules able to redirect pre-mRNA splicing of specific targets. Recently, we have shown promising results employing AON-based therapy in cultured lymphoblastoid and fibroblast cells of LCA patients homozygously carrying the intronic CEP290 mutation. Correct splicing, ciliation and cilium length were almost completely rescued, and CEP290 protein levels significantly increased after AON treatment. The aim of this work is to further develop this therapeutic strategy, by employing viral vectors that express these AONs.

Methods: Different AONs were cloned into AAV vectors and their efficacy was assessed by co-transfecting the different AON together with a mini-gene containing the intronic mutation.

Results: RT-PCR analysis revealed two highly effective AON-containing AAV-vectors that were able to redirect normal CEP290 pre-mRNA splicing. Currently, we are analyzing the tropism of several AAV serotypes to determine the most potent one for transducing fibroblast cell lines. Subsequently, we will generate AON-containing AAVs to assess their therapeutic efficiency by RT-PCR, immunodetection of CEP290 protein levels, ciliation and cilium length in patient’s fibroblast cells.

Conclusions: Herewith, we demonstrate the therapeutic potential of AAV-based delivery of AONs to treat CEP290-associated LCA.

Keywords: 538 gene transfer/gene therapy • 411 adenovirus  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×